Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration

Schizophrenia Research

Volumn 37, Issue 1, 1999, Pages 97-106

  Akiyama, Kazufumi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cytokine; Immune system; Interleukin 1 receptor antagonist; Interleukin 2 soluble receptor ; Interleukin 6; Schizophrenia

Indexed keywords

BIPERIDEN; BROMPERIDOL; BROTIZOLAM; EMONAPRIDE; FLUNITRAZEPAM; FLUPHENAZINE; HALOPERIDOL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; NITRAZEPAM; PIPAMPERONE; RISPERIDONE; SULPIRIDE; TRIAZOLAM; UNCLASSIFIED DRUG; ZOPICLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; MALE; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-6; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0033522487     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00140-6     Document Type: Article

References (28)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). American Psychiatric Association, Washington, DC.
2. Bessler H., Levental Z., Karp L., Modai I., Djaldetti M., Weitzman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry. 38:1995;297-302.
3. Frommberger U.H., Bauer J., Haselbauer P., Fräulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 247:1997;228-233.
4. Ganguli R., Yang Z., Shurin G., Chengappa K.N.R., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51:1994;1-10.
5. Ganguli R., Brar J.S., Chengappa K.N.R., DeLeo M., Yang Z.W., Shurin G., Rabin B.S. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch. Gen. Psychiatry. 52:1995;668-672.
6. Ganguli, R., Gubbi, A., 1997. Clinical and immunological characteristics of a subgroup of patients suffering from schizophrenia. In: Ebert, D., Ebmeier, K.P., Kaschka, W.P., Rechlin, Th. (Series Eds.), Advances in Biological Psychiatry, vol. 18: Henneberg, A.E., Kaschka, W.P. (Eds.), Immunological Alterations in Psychiatric Diseases. Karger, Basel, pp. 35-43.
7. Hanisch U.-K., Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res. Rev. 21:1996;246-284.
8. Henneberg A.E., Horter S., Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr. Res. 14:1994;15-22.
9. Hornberg M., Arolt V., Wilke I., Kruse A., Kirchner H. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr. Res. 15:1995;237-242.
10. Katila H., Appelberg B., Hurme M., Rimón R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 12:1994;29-34.
11. Kay S.R., Opler L.A., Lindenmayer J.-P. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br. J. Psychiatry. 155(suppl 7):1989;59-65.
12. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:1994;346-351.
13. Maes M., Meltzer H.Y., Buckley P., Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur. Arch. Psychiatry Clin. Neurosci. 244:1995;325-329.
14. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., Berghmans R., Stans G., Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 21:1996;39-50.
15. McAllister, C.G., van Kammen, D.P., Kelley, M.E., 1997. Relapse prediction in schizophrenia: from monoamines to cytokines. In: Ebert, D., Ebmeier, K.P., Kaschka, W.P., Rechlin, Th. (Series Eds.), Advances in Biological Psychiatry, vol. 18: Henneberg, A.E., Kaschka, W.P. (Eds.), Immunological Alterations in Psychiatric Diseases. Karger, Basel, pp. 44-49.
16. Müller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 87:1993;66-71.
17. Müller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 247:1997;308-313.
18. Naudin J., Mège J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:1996;269-273.
19. Naudin J., Capo C., Giusano B., Mège J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr. Res. 26:1997;227-233.
20. Pollmächer T., Hinze-Selch D., Fenzel T., Kraus T., Schuld A., Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am. J. Psychiatry. 154:1997;1763-1765.
21. Rapaport M.H., Torrey E.F., McAllister C.G., Nelson D.L., Pickar D., Paul S.M. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur. Arch. Psychiatry Clin. Neurosci. 243:1993;7-10.
22. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr. Scand. 90:1994;311-315.
23. Rapaport M.H., McAllister C.G., Kim Y.S., Han J.H., Pickar D., Nelson D.L., Kirch D.G., Paul S.M. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol. Psychiatry. 35:1994;767-771.
24. Riecher-Rössler A., Löffler W., Munk-Jørgensen P. What do we really know about late-onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 247:1997;195-208.
25. Shintani F., Kanba S., Maruo N., Nakaki T., Nibuya M., Suzuki E., Kinoshita N., Yagi G. Serum interleukin-6 in schizophrenic patients. Life Sci. 49:1991;661-664.
26. Watkins L.R., Maier S.F., Goehler L.E. Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci. 57:1995;1011-1026.
27. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., Greenberg A.H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 643:1994;40-49.
28. Zhao B., Schwartz J.P. Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J. Neurosci. Res. 52:1998;7-16.